These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 38329411)

  • 1. Conversion of Host Cell Receptor into Virus Destructor by Immunodisc to Neutralize Diverse SARS-CoV-2 Variants.
    Hwang J; Kim BK; Moon S; Park W; Kim KW; Yoon JH; Oh H; Jung S; Park Y; Kim S; Kim M; Kim S; Jung Y; Park M; Kim JH; Jung ST; Kim SJ; Kim YS; Chung WJ; Song MS; Kweon DH
    Adv Healthc Mater; 2024 Jun; 13(14):e2302803. PubMed ID: 38329411
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ACE2-Decorated Virus-Like Particles Effectively Block SARS-CoV-2 Infection.
    Bayraktar C; Kayabolen A; Odabas A; Durgun A; Kok I; Sevinc K; Supramaniam A; Idris A; Bagci-Onder T
    Int J Nanomedicine; 2024; 19():6931-6943. PubMed ID: 39005960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
    Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
    Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of a bifunctional pan-sarbecovirus entry inhibitor targeting the cell receptor and viral fusion protein.
    Jin H; Cheng L; Gong Y; Zhu Y; Chong H; Zhang Z; He Y
    J Virol; 2023 Aug; 97(8):e0019223. PubMed ID: 37578234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2.
    Tada T; Fan C; Chen JS; Kaur R; Stapleford KA; Gristick H; Dcosta BM; Wilen CB; Nimigean CM; Landau NR
    Cell Rep; 2020 Dec; 33(12):108528. PubMed ID: 33326798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
    Glasgow A; Glasgow J; Limonta D; Solomon P; Lui I; Zhang Y; Nix MA; Rettko NJ; Zha S; Yamin R; Kao K; Rosenberg OS; Ravetch JV; Wiita AP; Leung KK; Lim SA; Zhou XX; Hobman TC; Kortemme T; Wells JA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28046-28055. PubMed ID: 33093202
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Lapaillerie D; Charlier C; Fernandes HS; Sousa SF; Lesbats P; Weigel P; Favereaux A; Guyonnet-Duperat V; Parissi V
    Viruses; 2021 Feb; 13(3):. PubMed ID: 33669132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Withanone from
    Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
    Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide Platform as a Powerful Tool in the Fight against COVID-19.
    Murdocca M; Citro G; Romeo I; Lupia A; Miersch S; Amadio B; Bonomo A; Rossi A; Sidhu SS; Pandolfi PP; Alcaro S; Sangiuolo FC; Novelli G
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants.
    Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN
    J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
    Xiang Y; Wang M; Chen H; Chen L
    Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
    Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
    J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago.
    Qiang M; Ma P; Li Y; Liu H; Harding A; Min C; Wang F; Liu L; Yuan M; Ji Q; Tao P; Shi X; Li Z; Li T; Wang X; Zhang Y; Wu NC; Lee CD; Zhu X; Gilbert-Jaramillo J; Zhang C; Saxena A; Huang X; Wang H; James W; Dwek RA; Wilson IA; Yang G; Lerner RA
    Adv Sci (Weinh); 2022 Jan; 9(1):e2102181. PubMed ID: 34716683
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain.
    Chi X; Liu X; Wang C; Zhang X; Li X; Hou J; Ren L; Jin Q; Wang J; Yang W
    Nat Commun; 2020 Sep; 11(1):4528. PubMed ID: 32913273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
    Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.